Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
You may also be interested in...
Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.
Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.
In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.